Aurinia Pharmaceuticals (NASDAQ:AUPH) versus BeOne Medicines (NASDAQ:ONC) Head-To-Head Review

Aurinia Pharmaceuticals (NASDAQ:AUPH) and BeOne Medicines (NASDAQ:ONC) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

Profitability

This table compares Aurinia Pharmaceuticals and BeOne Medicines’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	99.97%	26.62%	19.65%
BeOne Medicines	8.94%	12.06%	6.69%

Valuation and Earnings

This table compares Aurinia Pharmaceuticals and BeOne Medicines”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$283.05 million	7.63	$287.20 million	$2.17	7.74
BeOne Medicines	$5.74 billion	5.54	$286.93 million	$4.47	64.87

Aurinia Pharmaceuticals has higher earnings, but lower revenue than BeOne Medicines. Aurinia Pharmaceuticals is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. Comparatively, 48.5% of BeOne Medicines shares are owned by institutional investors. 12.2% of Aurinia Pharmaceuticals shares are owned by company insiders. Comparatively, 6.2% of BeOne Medicines shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings for Aurinia Pharmaceuticals and BeOne Medicines, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0	4	2	0	2.33
BeOne Medicines	1	1	11	2	2.93

Aurinia Pharmaceuticals currently has a consensus price target of $17.25, indicating a potential upside of 2.74%. BeOne Medicines has a consensus price target of $390.00, indicating a potential upside of 34.49%. Given BeOne Medicines’ stronger consensus rating and higher possible upside, analysts clearly believe BeOne Medicines is more favorable than Aurinia Pharmaceuticals.

Risk and Volatility

Aurinia Pharmaceuticals has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500. Comparatively, BeOne Medicines has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500.

Summary

BeOne Medicines beats Aurinia Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.